Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

162.80 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	669
Open	162.80
Bid (Size)	163.10 (100)
Ask (Size)	175.00 (200)
Prev. Close	162.80
Today's Range	162.80 - 162.80
52wk Range	60.00 - 200.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Belite Bio Q2 Earnings Call Highlights ↗

August 13, 2026

Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the...

Via MarketBeat

Full Transcript: Belite Bio Q2 2026 Earnings Call ↗

August 13, 2026

Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by...

Via Benzinga

Performance

YTD	+2.2%	+2.2%
1 Month	+8.5%	+8.5%
3 Month	+13.9%	+13.9%
6 Month	-7.4%	-7.4%
1 Year	+150.7%	+150.7%

More News

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

August 12, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

August 11, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

August 06, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases ↗

July 22, 2026

Via MarketBeat

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

July 20, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

July 15, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease ↗

July 09, 2026

Via MarketBeat

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

July 06, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

July 06, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

June 12, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 02, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Q1 Earnings Call Highlights ↗

May 20, 2026

Via MarketBeat

Belite Bio (BLTE) Q1 2026 Earnings Transcript ↗

May 20, 2026

Via The Motley Fool

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

May 20, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

May 18, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

May 15, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

May 13, 2026

From Belite Bio, Inc

Via GlobeNewswire

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

April 29, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

April 27, 2026

From Belite Bio, Inc

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026

April 23, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio to Participate in Four Upcoming Investor Conferences

April 23, 2026

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th

April 22, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

April 21, 2026

From Belite Bio, Inc

Via GlobeNewswire

Frequently Asked Questions

Is Belite Bio, Inc - American Depositary Shares publicly traded?

Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.

What exchange does Belite Bio, Inc - American Depositary Shares trade on?

Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?

The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market

What is the current price of Belite Bio, Inc - American Depositary Shares?

The current price of Belite Bio, Inc - American Depositary Shares is 162.80

When was Belite Bio, Inc - American Depositary Shares last traded?

The last trade of Belite Bio, Inc - American Depositary Shares was at 08/14/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.